Electroconvulsive therapy and biomarkers of neuronal injury and plasticity: Serum levels of neuron-specific enolase and S-100b protein

Psychiatry Research

Volumn 177, Issue 1-2, 2010, Pages 97-100

  Palmio, Johanna ^a,b   Huuhka, Martti ^b   Laine, Seppo ^b   Huhtala, Heini ^c   Peltola, Jukka ^b   Leinonen, Esa ^b   Suhonen, Jaana ^d   Keränen, Tapani ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d Jokilaakso Hospital   (Finland)

Author keywords

Depression; Glial activation; Neuron specific enolase; Neuronal injury; S 100b protein

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; NEURON SPECIFIC ENOLASE; PROTEIN S100B;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ELECTROCONVULSIVE THERAPY; FEMALE; GLIA CELL; HUMAN; MAJOR DEPRESSION; MALE; NERVE CELL LESION; NERVE CELL PLASTICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY RESISTANCE; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN INJURIES; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEURONAL PLASTICITY; PHOSPHOPYRUVATE HYDRATASE; S100 PROTEINS; TIME FACTORS;

EID: 77952098032     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.01.027     Document Type: Article

References (50)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatry Press, Washington, DC. 4th ed.
2. American Psychiatric Association The Practice of ECT: Recommendations for Treatment, Training and Privileging 2001, American Psychiatric Press, Washington, DC. 2nd ed.
3. Agelink M.W., Andrich J., Postert T., Würzinger U., Zeit T., Klotz P., Przuntek H. Relation between electroconvulsive therapy, cognitive side effects, neuron specific enolase, and protein S-100. Journal of Neurology, Neurosurgery and Psychiatry 2001, 71:394-396.
4. Anghelescu I., Klawe C.J., Bartensstein P., Szegedi A. Normal PET after long-term ECT. American Journal of Psychiatry 2001, 158:1527.
5. Arolt V., Peters M., Erfurth A., Wiesmann M., Missler U., Rudolf S., Kirchner H., Rothermundt M. S100B and response to treatment in major depression: a pilot study. European Neuropsychopharmacology 2003, 13:235-239.
6. Arts B., Peters M., Ponds R., Honig A., Menheere P., van Os J. S100 and impact of ECT on depression and cognition. Journal of ECT 2006, 22:206-212.
7. Berrouschot J., Rolle K., Kühn H.J., Schneider D. Serum neuron-specific enolase levels do not increase after electroconvulsive therapy. Journal of the Neurological Sciences 1997, 150:173-176.
8. Bloomfield S.M., McKinney J., Smith L., Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocritical Care 2007, 6:121-138.
9. Busnello J.V., Leke R., Oses J.P., Feier G., Bruch R.S., Quevedo J., Kapczinski F., Souza D.O., Cruz Portela L.V. Acute and chronic electroconvulsive shock in rats: effects on peripheral markers of neuronal injury and glial activity. Life Sciences 2006, 78:3013-3017.
10. Büttner T., Weyers S., Postert T., Sprengelmeyer R., Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997, 28:1961-1965.
11. Büttner T., Lack B., Jäger M., Wünsche W., Kuhn W., Müller T., Przuntek H., Postert T. Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures. Journal of Neurology 1999, 246:459-461.
12. Calev A., Cohen R., Tubi N., Nigal D., Shapira B., Kugelmass S., Lerer B. Disorientation and bilateral moderately supratreshold titrated ECT. Convulsive Therapy 1991, 7:99-110.
13. Coffey C.E., Weiner R.D., Djang W.T., Figiel G.S., Soady S.A., Patterson L.J., Holt P.D., Spritzer C.E., Wilkinson W.E. Brain anatomic effects of electroconvulsive therapy. A prospective magnetic resonance imaging study. Archives of General Psychiatry 1991, 48:1013-1021.
14. Cohen D., Taieb O., Flament M., Benoit M., Chevret S., Corcos M., Fossati P., Jeammet P., Allilaire J.F., Basquin M. Absence of cognitive impairment at long-term follow-up in adolescents treated with ECT for severe mood disorder. American Journal of Psychiatry 2000, 157:460-462.
15. Devanand D.P., Dwork A.J., Hutchinson E.R., Bolwig T.G., Sackeim H.A. Does ECT alter brain structure?. American Journal of Psychiatry 1994, 151:957-970.
16. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. International Journal of Biochemistry and Cell Biology 2001, 33:637-668.
17. Frank L. Electroshock: death, brain damage, memory loss, and brainwashing. Journal of Mind and Behavior 1990, 11:489-512.
18. Gábor G., Judit T., Zsolt I. Comparison of propofol and etomidate regarding impact on seizure threshold during electroconvulsive therapy in patients with schizophrenia. Neuropsychopharmacologia Hungarica 2007, 9:125-130.
19. Gerlai R., Roder J. Spatial and nonspatial learning in mice: effects of S100 beta overexpression and age. Neurobiology of Learning and Memory 1996, 66:143-154.
20. Greffe J., Lemoine P., Lacroix C., Brunon A.M., Terra J.L., Dalery J., Bernier E., Soares-Boucaud I., Rochet T., Leduc T.A., Balvay G., Mathieu P. Increased serum levels of neuron-specific enolase in epileptic patients and after electroconvulsive therapy-a preliminary report. Clinica Chimica Acta 1996, 244:199-208.
21. Jönsson H., Johnsson P., Höglund P., Alling C., Blumquist S. Elimination of S100B and renal function after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 2000, 14:698-701.
22. Lehtimäki K., Keränen T., Huuhka M., Palmio J., Hurme M., Leinonen E., Peltola J. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. Journal of ECT 2008, 24:88-91.
23. Leutmezer F., Wagner O., Baumgartner C. Serum s-100 protein is not a suitable seizure marker in temporal lobe epilepsy. Epilepsia 2002, 43:1172-1174.
24. Missler U., Wiesmann M., Friedrich C., Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997, 28:1956-1960.
25. Nardin P., Tramontina F., Leite M.C., Tramontina A.C., Quincozes-Santos A., de Almeida L.M., Battastini A.M., Gottfried C., Gonçalves C.A. S100B content and secretion decrease in astrocytes cultured in high-glucose medium. Neurochemistry International 2007, 50:774-782.
26. Nygaard Ø., Langbakk B., Romner B. Age-and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clinical Chemistry 1997, 43:541-543.
27. Palmio J., Peltola J., Vuorinen P., Laine S., Suhonen J., Keränen T. Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic-clonic seizures. Journal of the Neurological Sciences 2001, 183:27-31.
28. Persson L., Hårdemark H.G., Gustafsson J., Rundström G., Mendel-Hartvig I., Esscher T., Påhlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human nervous system. Stroke 1987, 18:911-918.
29. Pitkänen A., Sutula T.P. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurology 2002, 1:173-181.
30. Portela L.V.C., Tort A.B.L., Schaf D.V., Ribeiro L., Nora D.B., Walz R., Rotta L.N., Silva C.T., Busnello J.V., Kapczinski F., Gonçalves C.A., Souza D.O. The serum S100B concentration is age dependent. Clinical Chemistry 2002, 48:950-952.
31. Puri B.K., Oatridge A., Saeed N., Ging J.E., McKee H.M., Lekh S.K., Hajnal J.E. Does electroconvulsive therapy lead to changes in cerebral structure?. British Journal of Psychiatry 1998, 173:267.
32. Reisner A.D. The electroconvulsive therapy controversy: evidence and ethics. Neuropsychology Review 2003, 13:199-219.
33. Rose D., Fleischmann P., Wykes T., Leese M., Bindman J. Patient's perspectives on electroconvulsive therapy: systematic review. British Medical Journal 2003, 326:1363-1365.
34. Rosén H., Rosengren L., Herlitz J., Blomstrand C. Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke 1998, 29:473-477.
35. Sackeim H.A. The cognitive effects of electroconvulsive therapy. Cognitive Disorders: Pathophysiology and Treatment 1992, 183-228. Marcel Dekker, New York. L.J. Thal, W.H. Moos, E.F. Gamsy (Eds.).
36. Sackeim H.A., Prudic J., Devanand D.P., Kiersky J.E., Fitzsimons L., Moody B.J., McElhiney M.C., Coleman E.A., Settembrino J.M. Effect of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New England Journal of Medicine 1993, 328:839-846.
37. Sackeim H.A., Prudic J., Fuller R., Keilp J., Lavori P.W., Olfson M. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology 2007, 32:244-254.
38. Savola O., Pyhtinen J., Leino T.K., Siitonen S., Niemelä O., Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. Journal of Trauma 2004, 56:1229-1234.
39. Schroeter M.L., Abdul-Khaliq H., Diefenbacher A., Blasig I.E. S100B is increased in mood disorders and may be reduced by antidepressant treatment. NeuroReport 2002, 13:1675-1678.
40. Schroeter M.L., Abdul-Khaliq H., Krebs M., Diefenbacher A., Blasig I.E. Serum markers support disease-specific glial pathology in major depression. Journal of Affective Disorders 2008, 111:271-280.
41. Sterling P. ECT damage is easy to find if you look for it. Nature 2000, 403:242.
42. Swartz C.M., Abrams R. ECT Instruction Manual 1996, Somatics Inc, Lake Bluff, Illinois. 6th ed.
43. Szabo K., Hirsch J.G., Krause M., Ende G., Henn F.A., Sartorius A., Gass A. Diffusion weighted MRI in the early phase after electroconvulsive therapy. Neurological Research 2007, 29:256-259.
44. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003, 361:799-808. The UK ECT Review Group.
45. Wahlund B., von Rosen D. ECT of major depressed patients in relation to biological and clinical variables: a brief overview. Neuropsychopharmacology Supplement 2003, 28:21-26.
46. van der Wurff F.D., Stek M.L., Hoogendijk W.J., Beekman A.T. The efficacy and safety of ECT in depressed older adults: a literature review. International Journal of Geriatric Psychiatry 2003, 18:894-904.
47. Whitaker-Azmitia P.M., Azmitia E.C. äAstroglial 5-HT1a receptors and S-100 beta in development and plasticity. Perspectives on Developmental Neurobiology 1994, 2:233-238.
48. Whitaker-Azmitia P.M., Wingate M., Borella A., Gerlai R., Roder J., Azmitia E.C. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Research 1997, 776:51-60.
49. Zachrisson O.C.G., Balldin J., Ekman R., Naesh O., Rosengren L., Ågren H., Blennow K. No evident neuronal damage after electroconvulsive therapy. Psychiatry Research 2000, 96:157-165.
50. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S100 protein family: history, function, and expression. Brain Research Bulletin 1995, 37:417-429.